ClinicalTrials.gg
RecruitingNCT04433572TANGO-3Updated Aug 5, 2025

Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee

A Phase 3 interventional study of Temsirolimus and Saline placebo in Peripheral Artery Disease and Critical Limb Ischemia, sponsored by Mercator MedSystems, Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-05.

Primary conditionChronic Limb-Threatening IschemiaRegistry: Peripheral Arterial DiseaseReclassifiedWhy we changed it
Registry
Peripheral Arterial Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chronic Limb-Threatening Ischemia
Why
  1. The study's listed conditions name Chronic Limb-Threatening Ischemia, a narrower term within Peripheral Arterial Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Mercator MedSystems, Inc. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States — 13 open to participants now, 20 under way, 2 of them phase 3. Chronic Limb-Threatening Ischemia · United States.

Planned enrollment
7th of 82
250 · median 38
Started
2025
with 3 others
Phase 3
9 of 105
1 open now
Primary completion
2028-02
later than 17 of 19 live
Registered
84th of 105
by date

Among the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, this one is the 7th largest by planned enrollment of the 82 interventional ones that give a count, is one of 4 that started in 2025, is one of 9 in phase 3, reaches primary completion later than 17 of the 19 other live ones, and was the 84th registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

13 of the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, or all of them as a file.
02

Study summary

A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of Temsirolimus Perivascular Injection 0.1 mg/mL on the incidence of ischemia-driven major amputation, clinically driven target lesion revascularization, and clinically relevant target lesion occlusion after revascularization of lesions below the knee in patients with symptomatic Rutherford 3-5 peripheral artery disease. The primary safety endpoint will be gathered at 1-month post-index procedure. The primary efficacy endpoint will be gathered at 6 months post-index procedure. Participants will be followed for up to 5 years post-index procedure.

Read the detailed description

After completion of revascularization therapy and any decision to place stents, participants will be qualified for final enrollment in the study and will be randomized 2:1 and treated with the investigational drug or placebo, respectively. Any stents will be placed only after randomization, assignment, and adventitial drug therapy, although any stenting decisions (other than for treatment of AEs) must be made prior to randomization and adventitial drug delivery in order to avoid bias toward or against stenting.

03

Conditions studied

  • Peripheral Artery Disease
  • Critical Limb Ischemia

Browse trials for

04

In context

Chronic Limb-Threatening Ischemia Reclassified

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

This study's planned enrollment of 250 is above the median of 41 across 240 interventional studies indexed under Chronic Limb-Threatening Ischemia.

Browse Chronic Limb-Threatening Ischemia studies →

Lead sponsor

Mercator MedSystems, Inc. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Compared within Chronic Limb-Threatening Ischemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Arterial Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Pre-procedural:

  1. Participant has signed and dated , is capable of understanding the nature, significance and implications of the clinical trial, and is willing to comply with all study procedures and follow-up visits for the duration of the study.
  2. Participant is male or female, aged 18 years or older.
  3. If participant is female and of : agreement to use a highly effective (abstinence is acceptable) for at least 90 days after study treatment.
  4. Participant has severe claudication (Rutherford 3) or chronic limb-threatening ischemia (CLTI) (Rutherford 4-5) in the Target Limb.

    Angiographic/Procedural:

  5. Participant has up to two de novo or restenotic Qualified Target Lesions meeting the following criteria, each based on the Investigator's visual assessment. Target Lesions should be considered separate if they are located in separate vessels (not in the same blood path) or have more than 10 cm intervening normal artery.

    Diameter

    1. ≥70% diameter stenosis anywhere within the Target Lesion or ≥50% diameter stenosis spanning at least 10 cm of length.
    2. Reference (normal) vessel diameter ≥2 mm and ≤8 mm. Location
    3. Any lesion chosen as a Target Lesion is in or spans at least one below-knee popliteal (P3 segment), tibial, or peroneal artery and is a culprit for dominant disease symptoms based on Investigator's assessment.
    4. ≥50% of the Target Lesion length is below the knee joint space (\<50% of Target Lesion length may extend above the midline of the knee joint space).
    5. ≥10 mm away from any previously placed stent or graft.
    6. A Target Lesion may cross an ostium of another artery (i.e. pass a bifurcation) but may only include one of the two branches. (Notes: Investigator should choose the dominant lesion for Target Lesion. Bifurcated lesions should be excluded, but if a lesion in a bifurcating vessel is separate from a Target Lesion based on intervening normal artery from which a proximal reference diameter can be measured, it may be treated as a second Target Lesion.) Length
    7. ≤30 cm in cumulative length from most proximal to most distal normal segment bounding the Target Lesion(s).
    8. A single Target Lesion may be comprised of multiple lesions or multifocal lesions (i.e. tandem lesions) if there is no continuous normal segment >10cm in length within the Target Lesion.
    9. Target Lesion may be in a vessel with another Target Lesion or above-knee non-target lesion if it is >10 cm away.
  6. Participant receives successful revascularization, based on the following Investigator visual assessments:

    1. Target Lesion and any treated non-target lesion in a Target Vessel or its inflow has \<30% residual stenosis, outflow has \<50% stenosis, and there is no flow-limiting dissection or perforation after treatment in an inflow vessel or Target Vessel.
    2. Participant has distal run-off into the foot with a patent named pedal artery.

Exclusion criteria

Exclusion Criteria

Pre-procedural:

  1. Participant is already enrolled in another clinical study of systemic or local vascular drug therapy or a vascular device study that has not completed its primary endpoint, including prior enrollment in this study.
  2. Participant is pregnant, nursing, or planning to become pregnant during the first 12 months after their enrollment in the study.
  3. Participant has presence of another anatomic or comorbid condition, or other medical, social, or psychological condition that, in the investigator's opinion, could limit the participant's ability to complete the clinical investigation or comply with follow-up requirements.
  4. Incapacitated individuals, defined as persons who are mentally ill, mentally handicapped, or individuals without legal authority, are excluded from the study population.
  5. Participant has a of ≤1 year.
  6. Participant received in the prior 2 months, is currently receiving, or is planned to receive systemic therapy, immunotherapy or chemotherapy.
  7. Participant has count \< 100,000 cells per microliter or > 700,000 cells per microliter, or \< 7.5 g/dL.
  8. Participant is unable to receive H1 antihistamine, temsirolimus or iodinated contrast medium due to labeled or known sensitivity reactions except for contrast allergies for which adequate prophylaxis may be used.
  9. Participant has a CNS tumor.
  10. Participant has had a myocardial infarction within the 30 days prior to study procedure.
  11. Participant has had a cerebrovascular accident within the 90 days prior to the study procedure.
  12. Participant has had an intracerebral hemorrhage within the 1 year prior to the study procedure.
  13. Participant has had any vascular surgical or endovascular procedure performed within the 30 days prior to the Index Procedure or planned within the 30 days after the Index Procedure; allowable exceptions to this exclusion include the following:

    1. Procedures performed during the same setting as the Index Procedure.
    2. Prior staged revascularization in the Target Limb but not the Target Lesion (e.g. for inflow revascularization) within the 30 days prior to the Index Procedure.
  14. Participant has a patent, previously implanted bypass graft within 3 cm of the Target Lesion.
  15. Participant is bedridden or unable to walk (with assistance is acceptable). Participants in wheelchair who are able to mobilize on their own can be enrolled.
  16. Participant has a planned major (above the ankle) amputation in the Target Limb.
  17. Participant has had any amputation to the ipsilateral extremity other than the toe or forefoot, or has had major amputation to the contralateral extremity \< 1 year prior to index procedure and is not independently ambulating.
  18. Participant has signs or symptoms of advanced limb infection or septicemia (fever > 38.5℃, white blood cell count > 15,000 cells per microliter, hypotension) at the time of assessment. Osteomyelitis of the phalanges or metatarsal heads or cellulitis of the foot amenable to treatment with IV antibiotics at the time of revascularization is acceptable.
  19. Participant has extensive tissue loss salvageable only with complex foot reconstruction or non-traditional amputations (e.g. Chopart or Lisfranc extending more proximal than a traditional transmetatarsal amputation), including any of the following conditions:

    1. Osteomyelitis that extends proximal to the metatarsal heads. Osteomyelitis limited to the phalanges or metatarsal heads is acceptable for enrollment.
    2. Any of the following involving the plantar skin of the forefoot, midfoot, or heel that cannot be effectively removed with a transmetatarsal amputation:

    i) Gangrene. ii) Deep ulcer (penetrating deeper than the dermis to subcutaneous structures involving facia, muscle or tendon).

    iii) Large shallow ulcer (not penetrating deeper than the dermis and >3cm in any measurement).

    c) Full thickness heel ulcer with or without calcaneal involvement. d) Any wound with calcaneal bone involvement. e) Dorsal wound with extensive necrosis requiring planned amputation more proximal than a transmetatarsal amputation.

    f) Wounds that are deemed to be neuropathic or non-ischemic in nature. g) Wounds that would require flap coverage or complex wound management for large soft tissue defect.

  20. Participant has a level of >1.5xULN ().
  21. Participant has an estimated (eGFR) less than 30 mL/min, except for patients with end stage renal disease on stable, chronic dialysis.

    Angiographic/Procedural:

  22. Participant has severe, advanced atherosclerotic peripheral artery disease (treated or left untreated) in the Target Limb which, in the opinion of the Investigator, has limited likelihood of a successful outcome.
  23. Participant has stenotic lesions, flow limiting dissection, or complication in any of the inflow or outflow vessels in the flow path of the Target Lesion, left untreated or after treatment, with residual stenosis >30% based on the Investigator's visual assessment.
  24. Participant receives or has received external radiation therapy to the target limb, vascular brachytherapy, cryotherapy, or drug-coated balloon (DCB) as part of the Target Lesion treatment during the index procedure or previous 6 months.
  25. Participant has been treated with a non-resorbable stent/scaffold in the Target Lesion in a prior setting (i.e. in-stent restenosis) or a bioresorbable scaffold in the Target Lesion in the previous 12 months.
  26. Participant has a severe (Type C or worse) dissection within the Target Lesion after revascularization but prior to Bullfrog drug delivery.
  27. Participant has an untreated aneurysm in the iliac, common femoral, superficial femoral, popliteal, or Target Vessel of the ipsilateral limb.
  28. Participant has visible thrombus requiring thrombolysis, percutaneous thrombectomy, or other treatment for acute limb ischemia of the Target Limb.
  29. Participant has angiographic evidence of thromboembolism or atheroembolism in the ipsilateral extremity upon completion of the intervention. (Pre- and post-angiographic imaging must confirm the absence of emboli in the distal anatomy.)
  30. Participant has a Target Lesion that cannot be crossed with a guide wire; however, subintimal wire crossing is allowed.
  31. Participant has heavy calcification at Target Lesion, which in the judgment of the investigator would prevent penetration of the Micro-Infusion Device needle through the vessel wall across the majority of the Target Lesion.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Active comparator
    Temsirolimus

    Temsirolimus delivered to adventitia and perivascular tissue after primary revascularization

    Drug: Temsirolimus

  • Placebo comparator
    Placebo

    Saline placebo delivered to adventitia and perivascular tissue after primary revascularization

    Drug: Saline placebo

Interventions

  • 0.1 mg/mL temsirolimus, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.

  • DrugSaline placebo

    Saline placebo, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.

07

What researchers measure

Primary outcomes

  1. Freedom from Cinical Relevant Target Lesion Failure

    Superiority of treatment vs. control group in the composite freedom from the following: * Clinically Relevant Target Lesion Occlusion * Clinically Driven Target Lesion Revascularization * Ischemia-Driven Major Amputation of the Target Limb

    Time frame: 6 Months

  2. MALE + POD

    Noninferiority of treatment vs. control groups in the composite freedom from Major Adverse Limb Event (MALE) in the target limb or Perioperative Death (POD)

    Time frame: 30 Days

Secondary outcomes

  1. Rate of clinically relevant restenosis (CRR)

    Superiority of treatment vs. control group in the rate of clinically relevant restenosis (CRR)

    Time frame: 6 months

  2. Freedom from target lesion failure (TLF)

    Superiority of treatment vs. control group in the composite freedom from the following: * Target Lesion Occlusion * Clinically Driven Target Lesion Revascularization * Ischemia-Driven Major Amputation of the target limb

    Time frame: 6 Months

  3. Freedom from clinically relevant target lesion failure (CR-TLF)

    Superiority of treatment vs. control group in the composite freedom from the following: * Clinically Relevant Target Lesion Occlusion * Clinically Driven Target Lesion Revascularization * Ischemia-Driven Major Amputation of the target limb

    Time frame: 12 Months

  4. Rate of clinically relevant restenosis (CRR)

    Superiority of treatment vs. control group in the rate of clinically relevant restenosis (CRR)

    Time frame: 12 months

Other outcomes

  1. Safety and tolerability will be assessed from overall rate of adverse events (subclassified as major, serious, non-serious, unanticipated, revascularization procedure-related, device-related and drug-related).

    AEs/ARs will be categorized into one of the following: * MALE of the target limb * Non-MALE target limb SAE/SAR * Other SAE/SAR * Non-serious AE/AR AEs/ARs will further be classified as: * Expected * UADE * SUSAR AEs/ARs will also be classified for relatedness (definitely, probably, possibly or not) to the following: * Revascularization procedure * Use of the Bullfrog device * The study drug

    Time frame: 1, 6, 12, 24 months

  2. Freedom from target lesion failure metrics

    Individual endpoints measuring each of the following: * Freedom from clinically relevant target lesion failure (CR-TLF) * Freedom from target lesion failure (TLF) * Freedom from clinically relevant target lesion occlusion (CR-TLO) * Freedom from any target lesion occlusion (TLO) * Freedom from clinically relevant restenosis (CRR) of the target lesion

    Time frame: 1, 6, 12 and 24 months

  3. Freedom from MALE of the index limb and all-cause death

    In composite and separately, the following will be measured: * MALE of the index limb * All-cause death

    Time frame: 1, 6, 12, 24 months

  4. Long-term freedom from all-cause death

    Rate of freedom from all-cause death

    Time frame: 36, 48, 60 months

  5. Limb salvage

    Freedom from ischemia-driven major amputation

    Time frame: 1, 6, 12, 24 months

  6. Amputation-free survival

    Freedom from ischemia-driven major amputation of the target limb and all-cause death

    Time frame: 1, 6, 12, 24 months

  7. Thrombotic and embolic outcomes

    Examined separately: * Arterial thrombosis in the target limb * Peripheral embolization in the target limb * Acute limb ischemia in the target limb

    Time frame: 1, 6, 12, 24 months

  8. Patency rates

    Examined separately: * Primary patency rate * Primary assisted patency rate * Secondary patency rate

    Time frame: 1, 6, 12, 24 months

  9. Revascularization rates

    Examined separately: * Clinically driven target lesion revascularization (CD-TLR) * Clinically driven target vessel revascularization (CD-TVR) * Clinically driven target vessel revascularization distal to the target lesion * Clinically driven target vessel revascularization proximal to the target lesion

    Time frame: 1, 6, 12, 24 months

  10. Wound healing measures

    Examined separately: * Index wound assessment for healing * Index wound assessment for infection * Occurrence of new wound * Unassisted wound healing

    Time frame: 1, 6, 12, 24 months

  11. Rutherford score improvement

    Rutherford category and change from baseline

    Time frame: 1, 6, 12, 24 months

  12. WIfI score improvement

    WIfI category and change from baseline

    Time frame: 1, 6, 12, 24 months

  13. Primary and secondary sustained clinical improvement rates

    * Primary sustained clinical improvement rate * Secondary sustained clinical improvement rate

    Time frame: 1, 6, 12, 24 months

  14. Patient reported quality of life benefits (VascuQoL)

    VascuQoL results and change from baseline

    Time frame: 1, 6, 12, 24 months

  15. Patient reported outcomes (walking impairment questionnaire) benefits

    WIQ results and change from baseline

    Time frame: 1, 6, 12, 24 months

08

Study locations

2 of 2 sites recruiting
09

References and documents

Individual participant data

Plan to share: No — No, there is not a plan to make individual participant data available to other researchers.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Feb 2028, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2020
First posted
Jun 16, 2020
StartActual
Jul 30, 2025
Primary completionEst.
Feb 1, 2028
CompletionEst.
Aug 1, 2032
Last update
Aug 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04433572
Lead sponsor
Mercator MedSystems, Inc.
Responsible party
Sponsor
First posted
Jun 16, 2020
Start date
Jul 30, 2025
Primary completion
Feb 1, 2028 (estimated)
Completion
Aug 1, 2032 (estimated)
Last update
Aug 5, 2025

Study contacts

Kirk Seward, PhD
Contact
kseward@mercatormed.com
(510) 614-4555

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temsirolimus

Start the discussion